Trial Profile
A Canadian open-label study to evaluate the safety and effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriatic arthritis (PsA) (ACCLAIM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms ACCLAIM
- Sponsors Abbott Laboratories
- 17 Jun 2017 Results of post-hoc analysis data from two studies (ACCLAIM and ADEPT) presented at the 18th Annual Congress of the European League Against Rheumatism
- 03 May 2008 Status changed from in progress to completed
- 20 Feb 2007 New trial record.